LIWANLI Innovation Co Ltd - Asset Resilience Ratio
LIWANLI Innovation Co Ltd (3054) has an Asset Resilience Ratio of 12.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LIWANLI Innovation Co Ltd (3054) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how LIWANLI Innovation Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see LIWANLI Innovation Co Ltd assets under control.
Liquid Assets Composition Over Time
This chart breaks down LIWANLI Innovation Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 3054 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$100.63 Million | 12.97% |
| Total Liquid Assets | NT$100.63 Million | 12.97% |
Asset Resilience Insights
- Moderate Liquidity: LIWANLI Innovation Co Ltd has 12.97% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
LIWANLI Innovation Co Ltd Industry Peers by Asset Resilience Ratio
Compare LIWANLI Innovation Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for LIWANLI Innovation Co Ltd (2003–2024)
The table below shows the annual Asset Resilience Ratio data for LIWANLI Innovation Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.30% | NT$89.50 Million ≈ $2.82 Million |
NT$792.19 Million ≈ $24.96 Million |
-1.86pp |
| 2023-12-31 | 13.16% | NT$109.75 Million ≈ $3.46 Million |
NT$834.17 Million ≈ $26.28 Million |
+2.07pp |
| 2022-12-31 | 11.09% | NT$89.35 Million ≈ $2.82 Million |
NT$805.93 Million ≈ $25.39 Million |
-20.02pp |
| 2021-12-31 | 31.11% | NT$294.88 Million ≈ $9.29 Million |
NT$947.90 Million ≈ $29.86 Million |
+18.46pp |
| 2020-12-31 | 12.65% | NT$126.93 Million ≈ $4.00 Million |
NT$1.00 Billion ≈ $31.61 Million |
-0.92pp |
| 2019-12-31 | 13.57% | NT$153.91 Million ≈ $4.85 Million |
NT$1.13 Billion ≈ $35.73 Million |
+1.48pp |
| 2018-12-31 | 12.10% | NT$128.45 Million ≈ $4.05 Million |
NT$1.06 Billion ≈ $33.45 Million |
+7.35pp |
| 2017-12-31 | 4.74% | NT$76.14 Million ≈ $2.40 Million |
NT$1.61 Billion ≈ $50.59 Million |
-15.43pp |
| 2016-12-31 | 20.17% | NT$350.08 Million ≈ $11.03 Million |
NT$1.74 Billion ≈ $54.68 Million |
+2.91pp |
| 2015-12-31 | 17.26% | NT$286.37 Million ≈ $9.02 Million |
NT$1.66 Billion ≈ $52.26 Million |
+3.08pp |
| 2014-12-31 | 14.18% | NT$271.65 Million ≈ $8.56 Million |
NT$1.92 Billion ≈ $60.37 Million |
+8.28pp |
| 2013-12-31 | 5.90% | NT$126.36 Million ≈ $3.98 Million |
NT$2.14 Billion ≈ $67.49 Million |
+0.24pp |
| 2012-12-31 | 5.66% | NT$83.87 Million ≈ $2.64 Million |
NT$1.48 Billion ≈ $46.70 Million |
-2.06pp |
| 2011-12-31 | 7.72% | NT$95.32 Million ≈ $3.00 Million |
NT$1.24 Billion ≈ $38.92 Million |
-26.50pp |
| 2009-12-31 | 34.21% | NT$422.14 Million ≈ $13.30 Million |
NT$1.23 Billion ≈ $38.88 Million |
+26.17pp |
| 2008-12-31 | 8.04% | NT$62.78 Million ≈ $1.98 Million |
NT$781.16 Million ≈ $24.61 Million |
+3.11pp |
| 2007-12-31 | 4.92% | NT$36.46 Million ≈ $1.15 Million |
NT$740.41 Million ≈ $23.33 Million |
+4.47pp |
| 2005-12-31 | 0.45% | NT$2.41 Million ≈ $75.90K |
NT$533.37 Million ≈ $16.80 Million |
-4.63pp |
| 2004-12-31 | 5.08% | NT$48.95 Million ≈ $1.54 Million |
NT$963.72 Million ≈ $30.36 Million |
-8.87pp |
| 2003-12-31 | 13.95% | NT$174.46 Million ≈ $5.50 Million |
NT$1.25 Billion ≈ $39.41 Million |
-- |
About LIWANLI Innovation Co Ltd
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for male, female, elderly, and children. Its products include anti-aging desire, pro-active nutrients capsules, black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, algae DHA soft gels, shea butte… Read more